D.E. Shaw & Co’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-251,189
| Closed | -$24.4M | – | 4287 |
|
|
2019
Q3 | $24.4M | Sell |
251,189
-269,411
| -52% | -$27M | 0.03% | 688 |
|
|
2019
Q2 | $53.3M | Buy |
520,600
+309,229
| +146% | +$33.4M | 0.07% | 359 |
|
|
2019
Q1 | $24.1M | Sell |
211,371
-803,078
| -79% | -$59M | 0.03% | 645 |
|
|
2018
Q4 | $39.7M | Buy |
1,014,449
+425,666
| +72% | +$18.5M | 0.05% | 426 |
|
|
2018
Q3 | $32.1M | Buy |
588,783
+81,127
| +16% | +$5.55M | 0.04% | 562 |
|
|
2018
Q2 | $42M | Buy |
507,656
+272,845
| +116% | +$21.1M | 0.05% | 419 |
|
|
2018
Q1 | $15.6M | Buy |
234,811
+197,413
| +528% | +$11.4M | 0.02% | 774 |
|
|
2017
Q4 | $1.92M | Sell |
37,398
-3,431
| -8% | -$246K | ﹤0.01% | 2169 |
|
|
2017
Q3 | $3.64M | Sell |
40,829
-31,353
| -43% | -$2.38M | 0.01% | 1610 |
|
|
2017
Q2 | $4.31M | Buy |
72,182
+37,943
| +111% | +$2.12M | 0.01% | 1455 |
|
|
2017
Q1 | $1.83M | Buy |
34,239
+26,314
| +332% | +$1.56M | ﹤0.01% | 1911 |
|
|
2016
Q4 | $395K | Buy |
+7,925
| New | +$425K | ﹤0.01% | 2987 |
|
|
2016
Q3 | – | Sell |
-27,172
| Closed | -$1.39M | – | 3642 |
|
|
2016
Q2 | $1.39M | Buy |
27,172
+8,378
| +45% | +$358K | ﹤0.01% | 2196 |
|
|
2016
Q1 | $555K | Sell |
18,794
-63,305
| -77% | -$2M | ﹤0.01% | 2731 |
|
|
2015
Q4 | $3.72M | Buy |
82,099
+69,155
| +534% | +$3.62M | 0.01% | 1646 |
|
|
2015
Q3 | $540K | Sell |
12,944
-5,049
| -28% | -$263K | ﹤0.01% | 3013 |
|
|
2015
Q2 | $1.08M | Buy |
+17,993
| New | +$1.19M | ﹤0.01% | 2651 |
|
D.E. Shaw & Co's ONCE Position: Q4 2019 in Review
D.E. Shaw & Co sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 251,189 shares — an estimated $24.4M sold.
D.E. Shaw & Co first reported a position in ONCE in Q2 2015 and held it in 17 quarters. The position peaked at $53.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- D.E. Shaw & Co reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- D.E. Shaw & Co sold 251,189 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $24.4M.
- D.E. Shaw & Co first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 17 quarters.
- D.E. Shaw & Co's Spark Therapeutics, Inc. Common Stock position peaked at $53.3M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.